Growth & profitability
- Revenue has declined 4.5% per year over the past 5 years.
- Operating margin has contracted, at -96.7% in the latest year.
BMRA Financials BIOMERICA INC
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$5M | 9.4% | -96.7% | — | — | $3M |
| 2024 | $5M | -$6M | 11.3% | -117.6% | -$5M | — | $4M |
| 2023 | $5M | -$7M | 8.4% | -135.3% | -$6M | — | $10M |
| 2022 | $19M | -$5M | 15.8% | -24.0% | -$536000 | — | $6M |
| 2021 | $7M | -$7M | 5.1% | -104.2% | -$5M | — | $4M |
| 2020 | $7M | -$3M | 26.0% | -41.0% | -$4M | — | $9M |
| 2019 | $5M | -$2M | 24.8% | -46.4% | -$2M | — | $686785 |
| 2018 | — | -$1M | — | — | -$1M | — | $1M |
| 2017 | — | -$908561 | — | — | -$818943 | — | $1M |
| 2016 | — | -$1M | — | — | -$300338 | — | $2M |
| 2015 | — | -$331410 | — | — | -$415984 | — | $1M |
| 2014 | — | -$215660 | — | — | -$999507 | — | $2M |
| 2013 | — | $536957 | — | — | $1M | — | $2M |
| 2012 | — | $548435 | — | — | -$17386 | — | $1M |
| 2011 | — | $157447 | — | — | $187719 | — | $989270 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Feb '26 | $987000 | -$1M | -4.5% | -131.5% | — | — | $1M |
| Nov '25 | $1M | -$1M | 4.2% | -113.5% | — | — | $3M |
| Aug '25 | $1M | $2000 | 30.7% | -81.0% | — | — | $3M |
| May '25 | $749000 | -$2M | -32.6% | -208.8% | — | — | $3M |
| Feb '25 | $1M | -$1M | 1.7% | -108.1% | — | — | $3M |
| Nov '24 | $2M | -$950000 | 26.7% | -60.7% | — | — | $2M |
| Aug '24 | $2M | -$1M | 16.0% | -75.7% | — | — | $3M |
| May '24 | $1M | -$1M | 1.8% | -136.9% | -$1M | — | $4M |
| Feb '24 | $1M | -$2M | -14.7% | -196.7% | -$2M | — | $5M |
| Nov '23 | $2M | -$2M | 20.7% | -102.6% | -$848000 | — | $7M |
| Aug '23 | $2M | -$1M | 24.1% | -71.9% | -$2M | — | $8M |
| May '23 | $1M | -$2M | 2.6% | -165.7% | -$963000 | — | $10M |
| Feb '23 | $1M | -$2M | 10.8% | -148.6% | -$2M | — | $3M |
| Nov '22 | $1M | -$2M | 23.8% | -112.4% | -$1M | — | $5M |
| Aug '22 | $2M | -$2M | -3.4% | -126.5% | -$2M | — | $6M |
| May '22 | $5M | -$2M | 11.7% | -33.1% | -$4M | — | $6M |
| Feb '22 | $8M | -$104168 | 21.8% | -1.4% | $2M | — | $10M |
| Nov '21 | $5M | -$1M | 16.6% | -24.3% | $1M | — | $7M |
| Aug '21 | $1M | -$2M | -7.0% | -122.1% | $70695 | — | $5M |
| May '21 | $1M | -$2M | 1.2% | -163.4% | -$1M | — | $4M |
Valuation over time
How the market has priced BMRA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 0.3× (Mar '23) to 1.0× (Jun '26).
P/S
Frequently asked questions
Is BMRA growing its revenue and profit?
Over the past 5 years, BIOMERICA INC's revenue has declined 4.5% per year. These are computed facts, not advice.
How much debt does BMRA have?
As of FY2025, BIOMERICA INC reported — of total debt against $3M of cash.
What is BMRA's profit margin?
In FY2025, gross margin was 9.4%, operating margin -96.7%, and net margin -93.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.